A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer (MONARCH)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Piramal Enterprises Limited
ClinicalTrials.gov Identifier:
NCT00824343
First received: January 15, 2009
Last updated: July 8, 2013
Last verified: July 2013
  Purpose

This is a single arm phase II trial to study the efficacy and safety of a Cdk inhibitor P276-00 in the treatment of squamous cell carcinoma of head and neck. Patients with recurrent or metastatic disease that is unresectable and incurable by radiation will be enrolled. Thirty eight evaluable patients need to be enrolled in the study. All patients will receive protocol treatment i.e. P276-00 as an intravenous infusion from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle till progression of disease or unacceptable toxicity. Safety evaluations by means of recording vitals, physical examination and lab investigations like hematology and clinical chemistry will be undertaken at regular intervals in each cycle. Tumor measurements by spiral CT scan will be undertaken at baseline and at the end of every 2 cycles for response evaluation by RECIST criteria. All patients will be followed up for survival status till one year of cycle 1 day 1.


Condition Intervention Phase
Squamous Cell Carcinoma of Head and Neck
Drug: P276-00
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Multicenter Phase II Study to Evaluate Efficacy and Safety of P276-00 in Indian Subjects With Recurrent, Metastatic or Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck

Resource links provided by NLM:


Further study details as provided by Piramal Enterprises Limited:

Primary Outcome Measures:
  • Response rate [ Time Frame: Tumor measurements to be undertaken at baseline and at the end of every 2 cycles. Response evaluation to be performed on the basis of RECIST criteria ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Duration of response, Progression free survival (PFS), Time to progression (TTP), PFS at one year, Overall survival (OS) at one year [ Time Frame: Tumor measurements at the end of every 2 cycles. Follow up for survival status every 4 weeks after discontinuation of protocol treatment till one year of cycle 1 day 1 ] [ Designated as safety issue: No ]

Enrollment: 86
Study Start Date: September 2008
Study Completion Date: June 2013
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single P276-00 arm
This is a single experimental arm study
Drug: P276-00
For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.

Detailed Description:

P276-00 was administered at a dose of 185mg/m2/day from day 1 to day 5 in each 21 day cycle. The protocol was amended in July 2009. As per the amendment P276-00 will be administered at a dose of 144 mg/m2/day from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle till progression of disease or unacceptable toxicity.33 patients have been recruited in version 1 protocol, 38 more evaluable patients need to be recruited in version 2 protocol. Allowing for approximately 30% drop-outs, it is estimated that, for enrolling 38 evaluable subjects in the study, approximately 54 subjects would be enrolled. As the study has already enrolled 33 subjects, the sample size for the study to accommodate for same number of subjects (38 evaluable) in the revised protocol is estimated as approximately 87 (33 + 54) subjects. Hence the total sample size (accounting for drop-outs) is 87 patients.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age more than or equal to 18 years
  2. Subjects with histologically or cytologically confirmed SCCHN that is recurrent and/or metastatic and judged incurable by surgery and/or radiation therapy and with zero to one line of chemotherapy for recurrent or metastatic disease at least 60 days prior to study entry.
  3. Measurable disease, defined as at least one unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥10 mm by spiral computerized tomography (CT) scan or magnetic resonance imaging (MRI)
  4. Tumor that is accessible to biopsy
  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  6. Life expectancy of at least three months
  7. Hemoglobin ≥ 8.0 gm/dL
  8. Absolute neutrophil count (ANC) ≥ 1000/mm3
  9. Platelet count ≥ 50,000/mm3
  10. Total bilirubin ≤1.5X institutional upper limit of normal (ULN)
  11. Serum AST ≤ 3X institutional ULN
  12. Serum ALT ≤ 3X institutional ULN
  13. Serum creatinine ≤1.5X institutional ULN
  14. Ability to understand and the willingness to sign a written informed consent document (ICD)

Exclusion Criteria:

  1. Nasopharyngeal carcinoma
  2. Prior treatment with P276-00 or other Cyclin dependent kinase (CDK) targeting agents
  3. History of allergic reactions attributed to compounds of similar chemical composition to P276-00
  4. Subjects who have received radiotherapy, chemotherapy or biologic/targeted anticancer agents within 60 days prior to Day 1 of study drug administration or have not recovered from adverse effects of any prior radiotherapy, chemotherapy or biologic/targeted agents.
  5. More than one chemotherapy regimen for the recurrent or metastatic disease
  6. Subjects who had received any other investigational drug within 1 month or within five half-lives of the other investigational agent, whichever is longer prior to Day 1 of study drug administration
  7. Subjects with QTc > 450 msec on 12 lead standard electrocardiogram (ECG)
  8. History of unstable angina or myocardial infarction or stroke within previous 6 months
  9. Subjects with uncontrolled inter-current illness including, but not limited to active infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  10. Subjects known to be suffering from infection with HIV, Tuberculosis, Hepatitis C or Hepatitis B
  11. Known brain metastasis
  12. History of prior malignancy except for curatively treated basal cell or squamous cell carcinoma of skin, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or any other cancer for which the subject has been disease-free for at least 3 years
  13. Women who are pregnant or lactating
  14. Women of childbearing potential [defined as sexually mature women who have not undergone hysterectomy or who have not been naturally postmenopausal for at least 24 consecutive months (i.e. who have had menses any time in the preceding 24 consecutive months)] and men, not agreeing to use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) prior to study entry (after signing the ICD), during the period of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilized
  15. Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the subject at an unacceptable risk or deems the subject not suitable for participation in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00824343

Locations
India
Bharath Hospital & Institute of Oncology, Mysore
Mysore, Karnataka, India, 570017
Regional Cancer Centre
Trivandrum, Kerala, India, 695011
Kashyap Nursing Home
Mumbai, Maharashtra, India, 400014
Jaslok Hospital, Mumbai
Mumbai, Maharashtra, India, 400026
Central India Cancer Research Institute,
Nagpur, Maharashtra, India, 440010
Deenanath Mangeshkar Hospital & Research Centre
Pune, Maharashtra, India, 411004
Bhagwan Mahaveer Cancer Hospital & Research Centre, Dept. Of Medical Oncology, Jaipur
Jaipur, Rajasthan, India, 302 017
V. N. Cancer Centre, GKNM Hospital,
Coimbatore, Tamilnadu, India, 641037
Dept. Of Surgical Oncology, CSM Medical University, Lucknow
Lucknow, UttarPradesh, India, 226003
Sponsors and Collaborators
Piramal Enterprises Limited
Investigators
Principal Investigator: Dr. Ajay Mehta Director and Onco-Surgeon, Central India Cancer Research Institute, Nagpur
Principal Investigator: Dr. M S Vishveshwara Radiation Oncologist, Bharat Hospital Institute of Oncology, Mysore
Principal Investigator: Dr. Sanjeev Misra Oncosurgeon, Department of Surgical Oncology, CSM Medical University, Lucknow
Principal Investigator: Dr. Rejnish Kumar Associate Professor, Regional Cancer Centre, Trivandram
Principal Investigator: Dr. Lalit Mohan Sharma Consultant Medical Oncologist, Bhagwan Mahavir Cancer Hospital and Research Centre, Jaipur
Principal Investigator: Dr. Maheboob Basade Medical Oncologist, Jaslok Hospital, Mumbai
Principal Investigator: Dr. Nilesh Lokeshwar, MD, DM Medical Oncologist
Principal Investigator: Dr. Chetan Deshmukh, MD, DM Medical Oncologist, Deenanath Mangeshkar Hospital and Research Centre, Pune, India
Principal Investigator: Dr. M Nagarajan, MD Radiation Oncologist, V. N. Cancer Centre, GKNM Hospital, Coimbatore, India
  More Information

No publications provided

Responsible Party: Piramal Enterprises Limited
ClinicalTrials.gov Identifier: NCT00824343     History of Changes
Other Study ID Numbers: P276-00/21/08
Study First Received: January 15, 2009
Last Updated: July 8, 2013
Health Authority: India: Drugs Controller General of India

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Carcinoma
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site

ClinicalTrials.gov processed this record on October 19, 2014